NeuroPsy InfoHub — informație de încredere despre neurodiversitate

Articole și ghiduri recomandate

VârstăToate vârstele Copii Tineri Adulți Vârstnici

StudiuParkinsonÎncredere înaltă27.06.2026

Glucagon-like peptide-1 receptor agonists in movement disorders: Mechanisms, evidence, and future directions

GLP-1 receptor agonists, originally developed for diabetes and obesity, show neuroprotective properties in preclinical models of movement disorders by modulating neuroinflammation, oxidative stress, and protein aggregation. Clinical evidence is most advanced in Parkinson's disease, though early promise from exenatide and lixisenatide trials was not confirmed in larger phase III studies, with preliminary signals emerging in other movement disorders.

StudiuParkinsonÎncredere înaltă23.06.2026

Brain Cholinergic Imaging in Isolated REM Sleep Behavior Disorder: Distinctions and Similarities with Parkinson's Disease

This PET neuroimaging study examined cholinergic terminal density in 16 patients with isolated REM sleep behavior disorder (iRBD, a prodromal stage of Parkinson's disease) compared to 12 Parkinson's patients and 18 controls. Both patient groups showed similar cortical cholinergic denervation (11-12% reduction) with distinct regional patterns, while iRBD showed associations between lower cholinergic uptake and impaired executive/visuospatial function.

StudiuParkinsonÎncredere înaltă23.06.2026

POLG-associated Parkinson's disease-ALS overlap: Novel variant and first use of continuous subcutaneous foslevodopa/foscarbidopa infusion

A 38-year-old patient with a rare POLG gene variant developed an unusual overlap syndrome combining young-onset Parkinson's disease with ALS-like features (Brait-Fahn-Schwartz disease). Continuous subcutaneous infusion of foslevodopa/foscarbidopa achieved significant motor improvement at twelve months, representing the first documented use of this device-based therapy in this genetic condition.

StudiuParkinsonÎncredere înaltă22.06.2026

Movement Disorder Society Statement on Biological Definition, Staging, and Classification of Parkinson's Disease

Official clinical guidance from the Movement Disorder Society providing an evidence-based biological definition, staging system, and classification framework for Parkinson's disease. This statement establishes standardized diagnostic and prognostic criteria for specialists managing the condition.

StudiuParkinsonÎncredere înaltă22.06.2026

Cognitive dysfunction in de novo Parkinson disease: Remitting vs. progressive cognitive impairment trajectories over five years

This longitudinal study tracked 258 newly diagnosed Parkinson's disease patients over five years, identifying three cognitive trajectory groups: cognitively normal, remitting decline, and progressive decline. Progressive cognitive decline was associated with depression, REM sleep behavior disorder, older age, lower education, elevated neurofilament biomarkers, and accelerated hippocampal volume loss, while remitting decline showed intermediate outcomes and olfactory dysfunction.

Informație de încredere. Sprijin real.

Explorează temele

Sănătate mintală și neurodezvoltare

Afecțiuni neurologice